Home › Trials › NCT05348733

Observational study on the use of Finerenone in patients with chronic kidney disease and type 2 diabetes.

FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting

Observational Bayer · NCT05348733

This study looks at how well the drug Finerenone works for adults with chronic kidney disease and type 2 diabetes who have recently started taking it.

Quick facts

Study typeObservational
Enrollment4500 (estimated)
Ages18 Years and up
SexAll
SponsorBayer Industry-sponsored
Locations68 sites (Huntsville, Alabama and 67 other locations)
Trial IDNCT05348733 on ClinicalTrials.gov

What this trial studies

This observational study aims to gather information on the use of the drug Finerenone in patients diagnosed with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Participants will be adults who have started treatment with Finerenone within 8 weeks prior to or after signing informed consent. The study will monitor the effects of Finerenone, which works by blocking mineralocorticoid receptors to potentially reduce kidney damage. The goal is to better understand the drug's effectiveness in a routine medical care setting.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with a diagnosis of chronic kidney disease associated with type 2 diabetes.

Not a fit: Patients who are currently participating in another investigational trial or have contraindications to Finerenone will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the effectiveness of Finerenone in managing kidney disease in patients with type 2 diabetes.

How similar studies have performed: While this study is observational, similar studies on Finerenone have shown promising results in managing kidney disease in diabetic patients.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adult participants of all genders (≥18 years old)
* Diagnosis of CKD associated with T2D based on assessment by physician.
* Treatment according to local marketing authorization, finerenone 20 or 10 mg.Treatment should have been started up to 8 weeks before or after the ICF is signed.
* Decision to initiate treatment with finerenone must be made before ICF is signed.
* Signed informed consent

Exclusion Criteria:

* Participation in an investigational trial at any time during the course of this study
* Contra-indications according to the local label.

Where this trial is running

Huntsville, Alabama and 67 other locations

+18 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Chronic Kidney DiseaseType 2 Diabetes Mellitus
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.